Dyne Therapeutics Posts Wider Q2 Loss of $1.08/Shr, Cash Runway Extended to 2029
DYN has more than doubled off its 52-week low of $8.88.
Summary
Dyne Therapeutics reported a Q2 2026 net loss of $(177.6) million, or $1.08 per share, wider than the $(0.73) loss in Q1. The company ended the quarter with $1.1 billion in cash, cash equivalents, and marketable securities, extending its cash runway into 2029. This follows a $375 million upsized public offering priced at $20.50 per share in late July, which bolstered the balance sheet. The wider loss reflects increased R&D spending as the company advances its neuromuscular pipeline, including the FDA's Priority Review of z-rostudirsen for Duchenne muscular dystrophy. The extended runway reduces near-term financing risk, but the burn rate remains high. Key upcoming catalysts include the FDA decision on z-rostudirsen and Phase 3 data for z-basivarsen.
At the time of this announcement, DYN was trading at $24.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $8.88 to $26.26. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.